Sometimes things move slowly, but sometimes they move fast 🏃
And sometimes even very fast.. 🏎
Remember the review we published here on $ZBIO stock, our research team identified that the CEO was accumulating shares while 3 different drugs were in various stages of trials. 🤫
Yesterday, the company announced that it completed Phase 2 of the trial for its leading multiple sclerosis drug - Obexelimab. ✅
The data was presented orally at a conference of the American Committee for Treatment and Research in Multiple Sclerosis held a few days ago in California. 💥
In response, the stock is jumping today by about 16%, completing a 37% rise since the post was published on the channel. 📈
This is exactly what behind-the-scenes information cross-referencing looks like, and as we said, sometimes the result comes quickly. ✨
We will continue to bring you quality information in the stock market 🔎